
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HUC2-565-A
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Drug-Drug Interaction Study Between HUC2-565-A and HUC2-565-B
Details : HUC2-565-A is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hypertension.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 01, 2024
Lead Product(s) : HUC2-565-A
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HUC2-344
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1 Study in Diabetes Mellitus(Fed)
Details : HUC2-344 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 13, 2024
Lead Product(s) : HUC2-344
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HUC2-344
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1 Study in Diabetes Mellitus(Fasting)
Details : HUC2-344 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 13, 2024
Lead Product(s) : HUC2-344
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lupin, Huons Sign Deal To Commercialize Cyclosporine in Mexico
Details : The agreement aims for the registration and marketing of Cyclosporine Ophthalmic Nanoemulsion, generic of Restasis, in Mexico.
Product Name : Restasis-Generic
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
July 22, 2024
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HUC3-053
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
To Evaluate the Efficacy and Safety of HUC3-053 in Patients with Dry Eye Syndrome
Details : HUC3-053 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dry Eye Syndromes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 29, 2024
Lead Product(s) : HUC3-053
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : NCP112
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Study for the Evaluation of Safety and Tolerability of NCP112 Eye Drops
Details : NCP112 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Xerophthalmia.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 16, 2024
Lead Product(s) : NCP112
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HU007
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
HU007 in Patients with Dry Eye Syndrome
Details : HU007 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dry Eye Syndromes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 24, 2023
Lead Product(s) : HU007
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HU-045
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 2 of HU-045 in Glabellar Lines
Details : HU-045 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glabellar Lines.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 28, 2022
Lead Product(s) : HU-045
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HU-014
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
To Evaluate HU-014 in the Treatment of Post Stroke Upper Limb
Details : HU-014 is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Muscle Spasticity.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 22, 2022
Lead Product(s) : HU-014
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : LIPAC Oncology
Deal Size : Undisclosed
Deal Type : Collaboration
LIPAC Oncology Announces Major Partnering Milestone Achieved in its License Agreement with Huons
Details : Clinical Study Report for a Phase 2A marker lesion clinical trial in patients with low-grade highly recurrent Non-Muscle Invasive Bladder Cancer treated with LiPax has been finalized. First milestone payment to LIPAC under the collaboration signed in In ...
Product Name : LiPax
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
December 10, 2020
Lead Product(s) : Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : LIPAC Oncology
Deal Size : Undisclosed
Deal Type : Collaboration
